GenIP (AIM:TEK), which provides AI-driven services to help research organisations and corporations commercialise their innovations, has given notice on its agreement with Phosphorix, moving to bring full operation of the Invention Evaluator platform in-house.
A three-month transition period will follow, during which Phosphorix continues providing support services before GenIP takes over technical management and development independently.
The company said the shift will let it retain the full product margin previously shared under the Phosphorix arrangement, while removing the monthly fixed fee and per-report charges that applied under the old deal.
GenIP also framed the move as a governance improvement, arguing that removing the related-party dependency strengthens compliance with the QCA Code.
Harin Vaghela joins as Chief Product Officer to manage the platform and lead product strategy, bringing over 15 years' experience building AI-powered enterprise platforms at Pasabi, LVMH and Black Swan Data.
"Bringing Invention Evaluator entirely in-house is a logical and commercially beneficial step for GenIP", said chief executive Melissa Cruz, adding that internalising the technology stack should improve margins and give the Company greater control over its development roadmap.
Cruz and chief financial officer Kevin Fitzpatrick will host an investor webinar via CMC CapX Spotlight on 24 September at 17:00 BST, open to existing and prospective shareholders with questions taken in advance or live.
News Intelligence what this means for the company
GenIP is internalising operation of its Invention Evaluator platform, ending a shared-margin arrangement with Phosphorix and eliminating monthly fixed fees and per-report charges. The move expands product margins, removes a related-party dependency that complicated QCA Code compliance, and gives GenIP direct control over the platform's development roadmap. The company has hired Harin Vaghela as Chief Product Officer to lead the transition, which runs for three months before GenIP assumes full technical management.
Internalisation should improve unit economics on Invention Evaluator by eliminating Phosphorix's take and fixed costs, supporting GenIP's stated target of gross margins above 60%. The move also clarifies governance and reduces execution risk by removing dependency on a third party for a flagship product, though success hinges on GenIP's ability to maintain platform quality and velocity during and after the transition.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
